Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
- Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. Erhardt, Wilma; Bergenheim, Klas; Duprat-Lomon, Isabelle; McEwan, Phil // Clinical Drug Investigation;2012, Vol. 32 Issue 3, p189
Background: The lack of adequate glycaemic control for patients with type 2 diabetes mellitus (T2DM), especially with existing second-line therapies, represents an unmet medical need. Of the newer therapies, the incretin-based medicines, such as saxagliptin, look promising to consolidate...
- Newer insulins in type 2 diabetes. Gale, Edwin A. M. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/22/2012, Vol. 345 Issue 7874, p44
No abstract available.
- Lifestyle changes pay off for diabetes. // PharmacoEconomics & Outcomes News;7/25/2009, Issue 583, p4
The article discusses studies on the cost effectiveness of lifestyle interventions aimed at preventing type 2 diabetes mellitus (T2DM) in high risk individuals. A diabetes progression model was used to assess the cost effectiveness of the intensive lifestyle and metformin interventions in the...
- Success for saxagliptin in South Africa. // PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p11
This section cites 3 studies on the cost-effectiveness of saxagliptin (Onglyza) for patients with type 2 diabetes mellitus, presented at the 17th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research. A. Juarez-Garcia and colleagues looked at the...
- Cost-effectiveness of insulin glargine versus sitagliptin in insulin naÃ¯ve patients with type 2 diabetes mellitus. Brown, S. T.; Sauriol, L. // Journal of Population Therapeutics & Clinical Pharmacology;2014, Vol. 21 Issue 1, pe132
Background: In the EASIE (Evaluation of insulin glargine versus Sitagliptin in Insulin-naive patients) trial, insulin glargine demonstrated a significant reduction in HbA1c compared to sitagliptin in type 2 diabetics who are inadequately controlled with metformin). The objective of this study...
- Combination Therapy of Canagliflozin and Metformin Extended Release Improves A1C Levels. // Journal of Psychosocial Nursing & Mental Health Services;2015, Vol. 53 Issue 8, p9
No abstract available.
- Pioglitazone combination therapy good value in type 2 DM. // PharmacoEconomics & Outcomes News;4/10/2004, Issue 450, p11
Discusses research being done on the cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus. Reference to a study by K. Neeser and colleagues, published in a 2004 issue of "PharmacoEconomics" journal; Benefits of the therapy for overweight diabetics; Use of a...
- The next step for insulin-resistant diabetics. R.M.D. // Cortlandt Forum;3/25/96, Vol. 9 Issue 3, p65
Discusses the advantages of adding oral agents to the regular medication regimen for an insulin-resistant patient with type II diabetes. Likelihood that such patients will not respond to oral agents.
- Once-daily insulin-sparing sulfonylurea for noninsulin-dependent diabetics. // Modern Medicine;Feb96, Vol. 64 Issue 2, p37
Reports that the United States Food and Drug Administration has cleared glimepiride (Amaryl) an insulin-sparing sulfonylurea for non-insulin dependent diabetics for marketing. Recommended dose; Side effects; Contraindications.